Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A

  • Authors:
    • Min Chen
    • Donna Voeller
    • Victor E. Marquez
    • Frederic J. Kaye
    • Patricia S. Steeg
    • Giuseppe Giaccone
    • Maria Zajac-Kaye
  • View Affiliations

  • Published online on: October 1, 2010     https://doi.org/10.3892/ijo_00000747
  • Pages: 963-971
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Aberrant hypermethylation at CpG sites within the CDKN2A gene is associated with silencing and has been proposed as a target for reactivation using both DNA methylation and histone deacetylation inhibitors. This study investigates the role of selecting tumor samples with a silenced as compared to deleted CDKN2A locus when assessing the efficacy of DNA methyltransferase inhibitor, zebularine, combined with the HDAC inhibitor, depsipeptide. Non-small cell lung cancer cell lines with defined CDKN2A status were analyzed by MTS assay to determine the effect of zebularine or zebularine combined with depsipeptide on tumor cell growth. We observed that zebularine treatment resulted in inhibition of cell growth in 11 out of 12 lung cancer cell lines with silenced CDKN2A, but no cell growth inhibition was detected in the 7 lung cancer cell lines tested with deleted CDKN2A (p>0.001). In addition, we found that the combination of 30 µM zebularine and 6 or 7 nM depsipeptide resulted in a synergistic inhibition of cell growth in tumor cells with silenced CDKN2A (p<0.001, CI=0.70 and 0.57, respectively) but not in tumor cells with deleted CDKN2A. In conclusion, tumor cells with methylated CDKN2A are more sensitive to zebularine than cell lines with deleted CDKN2A and the combination of zebularine/depsipeptide results in a synergistic effect on cell growth inhibition that is also linked with the presence of silenced CDKN2A. Thus, combination of DNA methyltransferase and HDAC inhibitors may be a potential treatment for lung cancer patients, but careful selection of patients will be needed to optimize the benefit of this regimen.

Related Articles

Journal Cover

October 2010
Volume 37 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen M, Voeller D, Marquez VE, Kaye FJ, Steeg PS, Giaccone G and Zajac-Kaye M: Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A. Int J Oncol 37: 963-971, 2010
APA
Chen, M., Voeller, D., Marquez, V.E., Kaye, F.J., Steeg, P.S., Giaccone, G., & Zajac-Kaye, M. (2010). Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A. International Journal of Oncology, 37, 963-971. https://doi.org/10.3892/ijo_00000747
MLA
Chen, M., Voeller, D., Marquez, V. E., Kaye, F. J., Steeg, P. S., Giaccone, G., Zajac-Kaye, M."Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A". International Journal of Oncology 37.4 (2010): 963-971.
Chicago
Chen, M., Voeller, D., Marquez, V. E., Kaye, F. J., Steeg, P. S., Giaccone, G., Zajac-Kaye, M."Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A". International Journal of Oncology 37, no. 4 (2010): 963-971. https://doi.org/10.3892/ijo_00000747